Cochrane · systematic review · CD012442
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
Peinemann, F, van Dalen, EC, Enk, H, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Childhood CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
5
Included studies
NR
No studies 5 · 71.4%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Dinutuximab‐containing immunotherapy compared to standard therapy for people with high‐risk neuroblastoma pre‐treated with autologous hematopoietic stem cell transplantation
Population: People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (reported as mortality) Dinutuximab‐containing immunotherapy vs standard therapy | HR 0.5 [0.31, 0.8] | 1 study · 226 participants | Moderate Downgraded: risk of bias, imprecision |
Treatment‐related mortality ‐ not reported Dinutuximab‐containing immunotherapy vs standard therapy | no estimate extracted | NR | No studies |
Progression‐free survival ‐ not reported Dinutuximab‐containing immunotherapy vs standard therapy | no estimate extracted | NR | No studies |
Event‐free survival (reported as relapse, progressive disease, secondary cancer, and mortality) Dinutuximab‐containing immunotherapy vs standard therapy | HR 0.61 [0.41, 0.92] | 1 study · 226 participants | Moderate Downgraded: risk of bias, imprecision |
Early toxicity ‐ not reported Dinutuximab‐containing immunotherapy vs standard therapy | no estimate extracted | NR | No studies |
Late non‐haematological toxicity ‐ not reported Dinutuximab‐containing immunotherapy vs standard therapy | no estimate extracted | NR | No studies |
Health‐related quality of life ‐ not reported Dinutuximab‐containing immunotherapy vs standard therapy | no estimate extracted | NR | No studies |